Rhythm Pharmaceuticals
RYTM
66 hedge funds and large institutions have $672M invested in Rhythm Pharmaceuticals in 2017 Q4 according to their latest regulatory filings, with 66 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
89.91% more ownership
Funds ownership: 0% → 89.91% (+90%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NMC
NEA Management Company
Timonium,
Maryland
|
+$130M |
| 2 |
O
OrbiMed
New York
|
+$76.7M |
| 3 |
MAM
MPM Asset Management
Boston,
Massachusetts
|
+$71.3M |
| 4 |
BBA
Baker Bros. Advisors
New York
|
+$54.2M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$34.4M |
Top Sellers
RYTM Hedge Fund Activity: Q4 2017 in Review
66 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Rhythm Pharmaceuticals (RYTM) for Q4 2017, worth a combined $672M.
Buyers outnumbered sellers: 66 funds opened new RYTM positions and 0 closed out — a net gain of 66 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was NEA Management Company, opening a new position worth an estimated $130M.
- 66 institutional investors held Rhythm Pharmaceuticals (RYTM) as of Q4 2017, up from 0 in Q3 2017.
- Funds reported $672M of Rhythm Pharmaceuticals stock for Q4 2017.
- 66 funds opened new Rhythm Pharmaceuticals positions in Q4 2017 and 0 closed out, a net change of +66 holders.
- The largest Rhythm Pharmaceuticals buyer in Q4 2017 was NEA Management Company, an estimated $130M added.
Based on aggregated 13F filings for Q4 2017.